Healthcare infrastructure · Pharmacy fulfillment
Truepill
The pharmacy behind a generation of direct to consumer health brands. It reached a $1.6 billion valuation in 2021, settled a federal controlled substances case in 2023, and sold in 2024 for a third of that.
A cold message on LinkedIn
Sid Viswanathan had sold a business card scanning app called CardMunch to LinkedIn, worked there as a product manager, and decided he wanted to build in healthcare. He knew nothing about pharmacy. So he went looking for somebody who did, and sent a cold InMail to a pharmacist named Umar Afridi.
“I messaged him just to get his thoughts on the pharmacy industry and what he’d seen, and that initial cold InMail on LinkedIn turned into several conversations back and forth over email over the next several weeks,” Viswanathan told The Business of Business in 2020.
Those conversations became Truepill. The two bootstrapped about 18 months before Y Combinator took them, Afridi filling prescriptions and Viswanathan packing boxes. Viswanathan later put it in one line: “Truepill is what happens when you lock a software engineer with a pharmacist in a room for long, long periods of time.”
The problem they picked
Any company that mails a prescription needs a licensed pharmacy standing behind it. That is not a software problem. It is a licensing, inventory and dispensing problem in fifty states, with a federal registration on top for controlled drugs.
Truepill sold that apparatus as a service. Its customers became the brands of the era: Nurx, Hims, GoodRx, Sesame, later Mark Cuban Cost Plus Drug Company. Forbes reported revenue of $48 million in 2018 on just $13 million of venture funding, and close to $100 million in 2019.
Then the pandemic arrived. Truepill stacked telehealth and at home diagnostics on top of fulfillment, and Viswanathan told TechCrunch in October 2021 it was positioned to bring in some $300 million in revenue that year. CNBC counted 800 new hires in a single year, up from 257 the year before; a former employee told Business Insider headcount reached about 1,800 by spring 2022.
When the customers became the risk
Truepill was the preferred pharmacy partner of Cerebral, the online mental health company that advertised ADHD treatment directly to consumers. In spring 2022, as reporting on Cerebral’s prescribing mounted, chain pharmacies began refusing its stimulant prescriptions. Truepill followed. “Out of an abundance of caution, Truepill is temporarily pausing all fulfillment of schedule 2 substances while we evaluate appropriate next steps,” it said in a statement to Fierce Healthcare. In June it shut down Ahead, the adult ADHD business it ran itself.
The money was going out faster than it came in. A former executive told Business Insider that Truepill burned an average of $12 million a month in 2022. Mark Cuban confirmed to the same outlet that he invested that November; two people said his money came on the condition that costs fall to $3 million a month. Four rounds of layoffs followed in a single year, and in 2023 the company closed pharmacies in Alhambra, California, Redmond, Washington and Austin, Texas.
The DEA case, from allegation to admission
On December 15, 2022, the Drug Enforcement Administration served Truepill with an Order to Show Cause. That is an administrative action opening the question of whether a DEA Certificate of Registration should be revoked. It is not a finding, and the DEA said so in the same release: until a determination is made, the action does not affect a registrant’s ability to handle controlled substances.
The allegations were specific. Between September 2020 and September 2022, Truepill filled more than 72,000 controlled substance prescriptions, 60 percent of them for stimulants including generic Adderall. In numerous instances, the agency said, those prescriptions were not issued for a legitimate medical purpose in the usual course of professional practice. The investigation also found prescriptions exceeding the 90 day supply limit, and prescriptions written by prescribers who lacked proper state licensing.
Truepill contested it. “We are confident we will be able to demonstrate the absence of wrongdoing,” Viswanathan told The Wall Street Journal that month.
Eleven months later the company settled. On November 6, 2023, the DEA Administrator said Truepill had accepted responsibility for three things: operating an unregistered online pharmacy, filling Schedule II prescriptions in excess of the 90 day limit, and filling prescriptions from providers without the required licenses. The first of those did not appear in the December 2022 release. Truepill agreed to revise its policies, retrain its pharmacists, and submit to heightened compliance measures for four years, a term running into November 2027. The DEA statement describes no monetary penalty, and no public record of one was found.
What is proven, and what is still claimed
| Evidence | What the record shows | Source type |
|---|---|---|
| DEA Order to Show Cause | Served Dec 15, 2022. Alleged more than 72,000 controlled substance prescriptions between Sep 2020 and Sep 2022, 60 percent stimulants; dispensing without legitimate medical purpose; over the 90 day limit; unlicensed prescribers. Allegations, not findings. | Public record |
| DEA settlement | Nov 6, 2023. Responsibility accepted on three counts. Remedies: revised policies, pharmacist training, four years of heightened compliance. No penalty stated. | Public record |
| 2022 position versus 2023 settlement | The CEO said the company was confident it could demonstrate the absence of wrongdoing. Eleven months later the DEA said it accepted responsibility for federal violations. | Claim differs from record |
| Form D filings | Four filings, CIK 0001796680, Dec 2019 to Sep 2023. Sold amounts total $307,491,954. The last sold $66,179,603 of $107,000,000 to 14 investors and lists neither founder. | Public record |
| Data breach | Files accessed Aug 30 to Sep 1, 2023: names, medication type, some demographic data, prescriber names; no Social Security numbers. Notices mailed Oct 30, 2023. Company and TechCrunch say 2.3 million patients; the HHS breach portal figure is 2.36 million. | Public record |
| Breach litigation | Reed v. PostMeds, Inc., N.D. Cal. 3:23-cv-05710. A $7.5 million settlement won preliminary approval Nov 26, 2024. | Public record |
| Layoff scale | TechCrunch sources put the August 2022 round at about a third of staff, roughly 175 people. The chief growth officer put it at 8 percent, and September at 20 percent of full time employees. | Reports differ |
| Economics at sale | Axios, citing internal documents, reported a $15 million loss on $64 million of revenue in early 2024. | Independent |
| Accreditation and scale | Seven pharmacies, URAC and NABP accreditation (2021). Three million patients and 20 million prescriptions (website, 2023). | Company-stated |
| FTC action | None naming Truepill was found. | Not found |
Read plainly: the operational story and the regulatory story are one story. Truepill grew by making it fast and cheap to mail medicine, and the record went wrong where speed met a controlled substance. The DEA alleged, the company said it would disprove, and eleven months later the agency said it had accepted responsibility. The second statement closed the matter.
What to watch
- The four year compliance term from the November 2023 settlement, running into November 2027.
- Whether the $200 million of revenue-linked earnouts reported by Axios is paid.
- Final approval and distribution in the PostMeds breach settlement.
- What survives under Fuze Health, launched May 2025 out of the merger. truepill.com now serves a product called FuzeRx.
In their words
“Truepill is what happens when you lock a software engineer with a pharmacist in a room for long, long periods of time.”
Sid Viswanathan, co-founder, The Business of Business, 2020 · Independent
“Out of an abundance of caution, Truepill is temporarily pausing all fulfillment of schedule 2 substances while we evaluate appropriate next steps.”
Truepill statement to Fierce Healthcare, April 2022 · Company-stated
“DEA will relentlessly pursue companies and pharmacies that seek to profit from unlawfully dispensing powerful and addictive controlled substances at the expense of the safety and health of the American people.”
Anne Milgram, DEA Administrator, Dec 15, 2022 · Public record
“We are confident we will be able to demonstrate the absence of wrongdoing.”
Sid Viswanathan, then CEO, to The Wall Street Journal, December 2022 · Company-stated
“With this settlement, Truepill has accepted responsibility for operating an unregistered online pharmacy, filling prescriptions for Schedule II controlled substances in excess of the 90-day limit, and filling prescriptions written by medical providers who did not have the required licenses, all in violation of federal law.”
Statement by the DEA Administrator, Nov 6, 2023 · Public record
“They just viewed volume as volume. They were trying to grow the business, and that was it.”
Former Truepill employee, to Business Insider, May 2023 · Independent
Related companies
Sources
- Public recordDEA serves Order to Show Cause on Truepill Pharmacy
- Public recordStatement by the Administrator on the Truepill settlement
- Public recordForm D, Truepill, Inc., CIK 0001796680, four filings
- Public recordReed v. PostMeds, Inc., 3:23-cv-05710, N.D. Cal.
- IndependentDEA alleges startup Truepill illegally dispensed Adderall
- IndependentTruepill’s run-in with the DEA
- IndependentA clash over online Adderall prescriptions
- IndependentThe pharmacy that quietly powered top startups
- IndependentTruepill’s Sid Viswanathan out as CEO as troubles mount
- IndependentTruepill conducts third round of layoffs in 2022
- IndependentTruepill conducts fourth round of layoffs in 2022
- IndependentTruepill says hackers accessed data of 2.3 million patients
- IndependentTruepill confirms the breach, and the HHS portal count
- IndependentTelehealth company Truepill gets swallowed for $525 million
- IndependentHow this B2B pharmacy startup made $200 million
- IndependentMark Cuban invested in digital health’s go-to pharmacy
- IndependentTruepill, CNBC Disruptor 50
- CompanyTruepill raises $142 million Series D
- CompanyLetsGetChecked completes acquisition of Truepill
- CompanyFuze Health launches
- CompanyFuzeRx site at truepill.com
Profile researched and written by Healthcare Discovery. Last updated September 29, 2026.
